To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Record year as licensing momentum drives a 24% increase in annualized recurring revenue1Near-record annual revenue drives all-time record levels of net income, adjusted EBITDA2, non-GAAP EPS3 and free-cash flow4 WILMINGTON, Del., Feb. 05, 2026 (GLOBE NEWSWIRE) -- InterDigital, Inc. (Nasdaq: IDCC), a wireless, video, and AI technology research and development company, today announced results for the fourth quarter and full year ended December 31, 2025. "We finished the year with another strong quarter to cap ...

Core Insights - Merck & Co., Inc. reported financial results for Q4 and full year 2025, highlighting a 5% increase in Q4 sales to $16.4 billion and a 1% increase in full-year sales to $65.0 billion, driven by strong demand for its innovative portfolio, particularly KEYTRUDA and new product launches [3][11][14] Financial Performance - Q4 2025 sales reached $16.4 billion, up from $15.6 billion in Q4 2024, marking a 5% increase [3] - Full-year sales for 2025 were $65.0 billion, compared to $64.2 billion in 2024, reflecting a 1% growth [11] - Non-GAAP EPS for Q4 2025 was $2.04, a 19% increase from $1.72 in Q4 2024, while full-year non-GAAP EPS was $8.98, up 17% from $7.65 in 2024 [30][11] Product Performance - KEYTRUDA sales in Q4 2025 were $8.4 billion, a 7% increase from $7.8 billion in Q4 2024, driven by strong global uptake in oncology [7] - GARDASIL sales declined by 34% in Q4 2025 to $1.0 billion, primarily due to lower demand in China and Japan [7] - Animal Health sales grew by 8% in 2025 to $6.4 billion, supported by higher demand for livestock products [16] Strategic Developments - The company completed the acquisition of Cidara Therapeutics for approximately $9.2 billion, enhancing its portfolio [37] - Merck announced positive late-stage trial results from 18 Phase 3 trials and initiated 21 new Phase 3 studies across various therapeutic areas [33] Regulatory and Pipeline Updates - The FDA approved KEYTRUDA and KEYTRUDA QLEX for the perioperative treatment of muscle-invasive bladder cancer [33] - The company is advancing its pipeline with significant regulatory milestones and ongoing studies in oncology, infectious diseases, and cardiometabolic areas [33][36] Future Outlook - For full-year 2026, Merck anticipates sales between $65.5 billion and $67.0 billion, with a non-GAAP effective tax rate expected between 23.5% and 24.5% [41][45] - Non-GAAP EPS for 2026 is projected to be between $5.00 and $5.15, including a one-time charge related to the acquisition of Cidara [46]

Core Points - The article discusses the importance of enabling Javascript and cookies in browsers to prevent access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1] Summary by Categories User Experience - Users are advised to enable Javascript and cookies to ensure smooth access to the website [1] - The presence of ad-blockers can lead to blocked access, suggesting a need for users to disable them for better experience [1]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Core Points - The article emphasizes the importance of enabling Javascript and cookies in browsers to prevent access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1] Summary by Categories Technical Requirements - Users are advised to enable Javascript and cookies in their browsers to ensure proper functionality [1] - The presence of ad-blockers can lead to blocked access, necessitating their temporary disablement [1]

Group 1 - The article does not provide any specific content related to a company or industry [1]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Core Insights - VIAVI Solutions Inc. has completed the acquisition of Spirent Communications plc's high-speed ethernet, network security, and channel emulation testing business for $425 million in cash [1][2] - The acquisition is expected to contribute approximately $180 million to VIAVI's Network Service Enablement revenue in the first year and be accretive to non-GAAP EPS within 12 months [2] Financial Details - The acquisition was financed through a senior secured term loan of $600 million from Wells Fargo Bank, maturing in seven years [3] - VIAVI plans to utilize its U.S. net operating losses to reduce the blended non-GAAP tax rate of the combined group [2] Strategic Implications - The acquisition enables VIAVI to enhance its product offerings in high-speed ethernet, network security, and channel emulation testing, providing a complementary and synergistic product portfolio across various verticals [7] - This strategic move positions VIAVI to better serve telecommunications, cloud, and enterprise markets [4]

Fiscal Year 2025 Guidance - CooperCompanies projects total revenue between $4,076 million and $4,096 million, representing organic growth of 4% to 4.5%[1] - CooperVision is expected to generate revenue between $2,734 million and $2,747 million, with organic growth of 4% to 5%[1] - CooperSurgical anticipates revenue between $1,343 million and $1,349 million, reflecting organic growth of 3% to 3.5%[1] - The company forecasts non-GAAP EPS to be in the range of $4.08 to $4.12[1] Q4 2025 Guidance - CooperCompanies estimates total revenue between $1,049 million and $1,069 million, indicating organic growth of 2% to 4%[1] - CooperVision's revenue is projected to be between $700 million and $713 million, with organic growth of 2% to 4%[1] - CooperSurgical expects revenue between $350 million and $356 million, showing organic growth of 2% to 4%[1] - The company predicts non-GAAP EPS to be between $1.10 and $1.14[1] Additional Information - Organic growth excludes the impact of acquisitions and discontinuations in the comparable period and is on a constant currency basis[2] - A reconciliation of non-GAAP measures to GAAP measures is available on the company's website[2] - The company has not provided reconciliation to GAAP for EPS guidance due to the difficulty in forecasting acquisition-related, integration, and restructuring charges and expenses[2]